Fresh analysis reveals that people who discontinue popular GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who halt traditional lifestyle plans.
Published data in a major health publication points out that while overweight people often shed substantial amounts of their total mass while undergoing treatment, the weight returns at an estimated rate of 0.8 kg per month after stopping.
"Individuals purchasing these medications should be cognizant of the risk of quick rebound weight gain when the treatment is stopped," warns lead investigator Dr. Susan Jebb.
Such speed of regain suggests a return to starting weight within about 18 months.
Comparing Therapies
The research, which reviewed dozens of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
Scientists point out that people who shed pounds through dieting usually experience a slower weight regain—perhaps 100 grams monthly—once they finish.
Understanding the Quick Rebound
Experts believe the mode of action of the drugs explains the amplified regain.
The injections mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing the hormone levels several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and may also diminish responsiveness to its effects," explained Dr. Adam Collins, a dietetics expert.
"Stopping of this GLP-1 'fix' means hunger is unsuppressed, making overeating a significant risk."
An Ongoing Condition?
Medical guidelines suggest the jabs for people with weight-linked medical conditions, accompanied by prescribed lifestyle changes.
Professionals say that, due to the likelihood of weight regain, the therapy is often life-long.
This perspective is reinforced by drug manufacturers, who note that the findings "emphasize the persistent character of obesity," akin to managing conditions like high blood pressure.
User Experiences
People who have discontinued the medication describe a powerful resurgence of cravings.
"It felt as if something flipping and I was suddenly starving," said an individual.
This difficulty is compounded if patients have not adopted lasting dietary or behavioural modifications during treatment.
Significant Interest
Figures indicate that a significant number of adults in the UK have used weight-loss jabs in the past year, with demand being substantial.
- Use is higher among females than men.
- The middle-aged age group shows the highest level of interest.
- A large proportion access the drugs through private prescriptions rather than the NHS.
Finally, researchers stress that while the jabs are powerful agents for shedding pounds, they are not a permanent cure and maintained weight loss hinges on ongoing behavioural support.
